In the short-to-medium term the priorities of these two senior directors or executive directors Global Process Development are to:
Working location: Wuxi, China
WuXi Advanced Therapies – Company Overview
The Advanced Therapies business unit of WuXi AppTec is a global Contract Development and Manufacturing Organization (CDMO) dedicated to accelerating and transforming development, manufacturing, and commercialization of cell, gene, and other advanced biopharmaceuticals.
Through continued internal reinvestment in facilities, technology, and talent combined with over three decades of biopharmaceutical testing expertise, WuXi Advanced Therapies have transformed their services for cell and gene therapy companies into solutions that alleviate industry bottlenecks, accelerate time to market, and support commercial programs around the world.
Serving clients that range from startup’s recently spun out of an academic institutions, to large pharma companies seeking to launch a product in new markets, WuXi Advanced Therapies integrated development, manufacturing, and testing services provide tailored services that are ideal for:
Their beginnings can be traced back to 1982 where, founded as ViroMed Laboratories (later AppTec) in the US, they offered clinical diagnostics with viral focus. Following the acquisition of AppTec by WuXi PharmaTech in 2008, the Philadelphia operations continued to manufacture cell banks and provide testing services for biopharmaceuticals, as WuXi AppTec. Integrated advanced therapies testing and manufacturing services were added in 2014, followed a year later by advanced therapies production (clinical & commercial scale) with the opening of 2 new facilities for cell therapy & gene therapy/viral vector manufacturing. In 2018 WuXi AppTec spun out advanced therapies manufacturing and testing operations in the US into a separate Business Unit; WuXi Advanced Therapies. Today, WuXi Advanced Therapies employ 600 staff across 4 facilities in the US and China. Turnover in 2019 is forecast to be in the region of US$150-200m
For more information, please visit the official website: www.advancedtherapies.com
WuXi AppTec Group is a leading global pharmaceutical, medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, WuXi AppTec Group provides a broad and integrated portfolio of services to help their worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities in small molecule R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, and medical device testing, WuXi platform is enabling more than 3,000 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfil WuXi AppTec Group’s dream that “every drug can be made and every disease can be treated”.
WuXi AppTec was developed from four founders and a single laboratory in 2001 to 26,000+ employees, 30+ R&D sites, manufacturing sites and offices worldwide, including 6+ million square feet of laboratory and manufacturing space, as well as facilities still under construction. The company is actively improving its capabilities and capacity through new expansions in its global business. Capitalizing on the advantage of conducting R&D services, WuXi AppTec is building an alternative R&D engine to serve the global life-science industry.
For more information, please visit the official website: www.wuxiapptec.com.cn
Equal Opportunity Employer Minorities/Women/Veterans/Disabled
Join our Talent Community so we can keep you informed about upcoming events and opportunities that match your interests.